Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America

Prolong Pharmaceuticals sponsored a Lunch and Learn at the 44th Annual Convention of the Sickle Cell Disease Association of America held in Baltimore MD.  This one hour venue provided patients, healthcare professionals and community based organizations an opportunity to better understand the need for improved transitional care in patients who leave the supportive structure of pediatric care and enter into adult care.

The lecture was given by Dr. Ify Osunkwo MD, MPH and Medical Director, Sickle Cell Program of the Levine Cancer Institute/Carolinas HealthCare System Charlotte NC and Clinical Associate Professor of Medicine University of North Carolina at Chapel Hill. She leads the initiative to establish a comprehensive, multi-disciplinary system of care for all adults living with SCD in the Charlotte Metro area, approximately 1300 individuals.

Prolong also announced the launch of a new website dedicated to assisting patients find clinical trials on sickle cell disease (SCD). The website, Scdtrialmap.com is sponsored by Prolong Pharmaceuticals.  The clinical trial information is derived from ClinicalTrials.gov, a Web-based resource maintained by the National Library of Medicine  at the National Institutes of Health (NIH). Scdtrialmap.com allows an individual to easily identify trials being held in any state in the United States.

“We are pleased to partner with SCDAA to provide another educational forum to the SCD community” state Glenn Kazo, President of Prolong Pharmaceuticals.  “This luncheon and the sponsorship of the Scdtrialmap.com are part of our commitment to provide resources and tools to the patients and families impacted by sickle cell disease.

SANGUINATE is currently in clinical trials for a number of indications in which hypoxia and inflammation play a role.  A Phase 2 study is underway in adult patients with vaso-occlusive crisis.  Other indications include patients with acute, severe anemia and the reduction of delayed graft function following kidney transplantation.